KRAS and lung adenocarcinoma: LKB1 activity is frequently compromised by somatic mutation and epigenetic regulation in lung adenocarcinoma, and KRAS/STK11 co-mutation results in worse prognosis than other KRAS-mutant subtypes due to a greater likelihood of metastasis and resistance to standard-of-care treatments, including immune checkpoint inhibitors (Skoulidis et al. 2018; Calles et al. 2015; Rosellini et al. 2022).